87亿美元打水漂?艾伯维Emraclidine精神分裂症2期试验失败

药渡
13 Nov 2024

11月11日,艾伯维宣布,以90亿美元收购 Cerevel的核心药物EMPOWER在两项针对精神分裂症患者的 II 期EMPOWER-1和EMPOWER-2临床试验中失败。Emraclidine 作为每日一次口服单一疗法治疗精神病症状急性加重的精神分裂症成人患者的疗效,未达到其主要终点,即阳性和阴性第 6 周时与安慰剂组相比的症状量表 (PANSS) 总分。EMPOWER-1研究中,患者按1:1...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10